RecruitingPhase 2NCT06080789

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Panafina, Inc.
Intervention
RABI-767(drug)
Enrollment
36 target
Eligibility
18-85 years · All sexes
Timeline
20242026

Study locations (15)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06080789 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials